Journal of Hematology & Oncology

Article	Citations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity	723
Targeting the Wnt/β-catenin signaling pathway in cancer	699
Nanomaterials for cancer therapy: current progress and perspectives	548
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19	493
EZH2: a novel target for cancer treatment	488
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer	396
NK cell-based cancer immunotherapy: from basic biology to clinical development	342
Next generation of immune checkpoint inhibitors and beyond	328
Regulation of PD-L1 expression in the tumor microenvironment	318
Roles of METTL3 in cancer: mechanisms and therapeutic targeting	294
Challenges and advances in clinical applications of mesenchymal stromal cells	284
Cancer vaccines as promising immuno-therapeutics: platforms and current progress	268
RNA sequencing: new technologies and applications in cancer research	266
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)	249
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy	246
Combination strategies to maximize the benefits of cancer immunotherapy	243
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis	236
Isolation and characterization of exosomes for cancer research	231
Dendritic cell biology and its role in tumor immunotherapy	225
Liquid biopsy: current technology and clinical applications	225
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling	222
Immunosenescence: a key player in cancer development	220
Novel therapies emerging in oncology to target the TGF-β pathway	217
Targeting mutant p53 for cancer therapy: direct and indirect strategies	216
Applications of single-cell sequencing in cancer research: progress and perspectives	214

Neutrophils in cancer carcinogenesis and metastasis	212
Targeting hypoxic tumor microenvironment in pancreatic cancer	211
Recent advances in therapeutic strategies for triple-negative breast cancer	210
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells	205
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research	203
Recent advances in CAR-T cell engineering	201
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response	198
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions	194
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)	187
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy	183
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma	178
Targeting CD47 for cancer immunotherapy	171
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019	167
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	167
RNA-binding proteins in tumor progression	166
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets	159
Targeting MCL-1 in cancer: current status and perspectives	159
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study	159
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy	155
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway	153
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	153
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies	150
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	147
MEK inhibitors for the treatment of non-small cell lung cancer	146
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti	144
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019	144
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target	144
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends	139
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape	139
Antibody–drug conjugates in solid tumors: a look into novel targets	138
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update	137
HMGB1 in inflammation and cancer	134
Modeling neoplastic disease with spheroids and organoids	133
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment	133
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1	131
Exploring immunotherapy in colorectal cancer	130
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies	129
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin	125
Role of lysosomes in physiological activities, diseases, and therapy	123
Mesenchymal stem/stromal cells in cancer therapy	122
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential	120
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy	118
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies	118
Targeting autophagy to overcome drug resistance: further developments	117
The management of metastatic GIST: current standard and investigational therapeutics	116
BCMA-targeted immunotherapy for multiple myeloma	115
Emerging agents and regimens for AML	113
Targeting Akt in cancer for precision therapy	111
tRNA-derived RNA fragments in cancer: current status and future perspectives	110
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies	109

Gastric cancer treatment: recent progress and future perspectives	107
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands	105
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma	102
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma	102
Targeting EphA2 in cancer	101
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation	101
Emerging strategies to target RAS signaling in human cancer therapy	100
The potential role of N7-methylguanosine (m7G) in cancer	100
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	98
The long and short non-coding RNAs modulating EZH2 signaling in cancer	98
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward	96
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents	96
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia	96
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer	96
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk	94
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma	92
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	90
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment	89
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC	87
Role of CD47 in Hematological Malignancies	86
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies	85
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks	83
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021	82
Novel therapies are changing treatment paradigms in metastatic prostate cancer	81
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA	80
New agents and regimens for diffuse large B cell lymphoma	80
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	80
Prostate cancer and PARP inhibitors: progress and challenges	78
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers	78
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	78
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications	78
Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study	77
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges	75
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia	74
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials	73
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors	73
Crosstalks between inflammasome and autophagy in cancer	73
FGFR-TKI resistance in cancer: current status and perspectives	73
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	73
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	72
Targeting immune checkpoints in hematological malignancies	72
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential	70
STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib	69
Born to survive: how cancer cells resist CAR T cell therapy	69
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management	68
Advances in the diagnosis and treatment of sickle cell disease	67
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies	67
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas	66
Tumor organoids: applications in cancer modeling and potentials in precision medicine	66
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors	66
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	65
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance	65
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors	65
Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application	64
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)	64
Targeting macrophages in hematological malignancies: recent advances and future directions	64
Third-line therapy for chronic myeloid leukemia: current status and future directions	64
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism	64
Natural killer cell-based immunotherapy for acute myeloid leukemia	63
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study	62
N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer	62
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity	60
Emerging strategies to overcome resistance to third-generation EGFR inhibitors	60
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	60
Thrombocytopenia and thrombosis in hospitalized patients with COVID-19	60
The emerging role of KDM5A in human cancer	59
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer	59
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	58
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes	57
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	57
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies	57
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies	57
Payload diversification: a key step in the development of antibody–drug conjugates	57
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	56
Emerging agents and regimens for multiple myeloma	56
CAR-T cells and BiTEs in solid tumors: challenges and perspectives	56
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	55
Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea	55
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	55
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors	54

Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy	54
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party o	54
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	54
Molecular pathogenesis of the myeloproliferative neoplasms	53
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer	52
Prognostic and predictive biomarker developments in multiple myeloma	52
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	52
Therapeutic strategies in RET gene rearranged non-small cell lung cancer	52
STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer	52
Beyond thrombosis: the impact of tissue factor signaling in cancer	52
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy	52
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	52
Circadian rhythms and cancers: the intrinsic links and therapeutic potentials	51
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	51
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	51
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	51
Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals	50
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies	50
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	50
The functions and clinical significance of circRNAs in hematological malignancies	50
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies	49
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities	49
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials	49
How we treat NK/T-cell lymphomas	49
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity	48
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matche	48
Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data	48
A single-cell survey of cellular hierarchy in acute myeloid leukemia	47
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial	47
Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism	47
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer	46
Interplay between endoplasmic reticulum stress and non-coding RNAs in cancer	46
Protein degradation technology: a strategic paradigm shift in drug discovery	46
Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment	46
Integrins regulate stemness in solid tumor: an emerging therapeutic target	45
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients	45
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)	45
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma	44
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers	44
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies	43
RETRACTED ARTICLE: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA	43
Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma	42
Drugging KRAS: current perspectives and state-of-art review	42
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia	42
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes	42
Molecular and cellular mechanisms of aging in hematopoietic stem cells and their niches	42
Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers	42
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia	41
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN	41
Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway	41
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer	41
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	41
Recent advances in targeted therapies in acute myeloid leukemia	41
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application	41
Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets	40
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress	40
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy	39
High-throughput approaches for precision medicine in high-grade serous ovarian cancer	39
Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis	39
Targeting oncogenic Notch signaling with SERCA inhibitors	39
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia	39
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia	38
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia	38
Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled t	38
Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma	38
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer	38
The biogenesis and biological function of PIWI-interacting RNA in cancer	38
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study	38
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination	38
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer	37
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	37
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer	37
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis	36
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	36
Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications	36
Current understanding of extrachromosomal circular DNA in cancer pathogenesis and therapeutic resistance	36
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting	36
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes	36
Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion	36
Current and future treatment strategies in chronic lymphocytic leukemia	35
Novel targeted therapies of T cell lymphomas	35
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia	35
LncRNA Snhg6 regulates the differentiation of MDSCs by regulating the ubiquitination of EZH2	34
Cancer cachexia: molecular mechanisms and treatment strategies	34
Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis	33
Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia	33
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status	33
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins	33
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity	33
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence	33
3D chromatin architecture and transcription regulation in cancer	32
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses	32
Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis	32
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study	32
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	32